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Objective: To evaluate the efﬁcacy and safety of fondaparinux compared with nadroparin for prevention
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Patients and methods: One hundred ﬁfteen patients were randomized into 2 treatment groups. Patients
were given fondaparinux in Group I and nadroparin in Group II. Measurements were performed on Days
1, 5, and 21. The wound area was assessed with a subjective visual analog scale.
Results: The blood counts, clinical biochemical tests, and coagulation tests (ie, thrombin time, partial
thromboplastin time, activated partial thromboplastin time, ﬁbrinogen, prothrombin time–
International Normalized Ratio, and antithrombin III activity) did not show statistically signiﬁcant
differences between Group I and Group II. In both study groups, anti-factor Xa activities increased
signiﬁcantly on the ﬁfth and 21st day. The scores of the subjective visual analog scale showed
signiﬁcance on Day 21.
Conclusions: Our results conﬁrm the safety and efﬁcacy of both fondaparinux and nadroparin for
prophylaxis after major orthopedic surgery.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Venous thromboembolism (VTE), which presents clinically as
deep vein thrombosis (DVT) and pulmonary embolism, is
the most frequent serious complication after major orthopedic
surgery of the lower extremities.1,2 At present, anticoagulant
prophylactic treatments such as low-dose heparin, low-
molecular-weight heparins (LMWHs), warfarin, or recombinant
hirudin are recommended, but the frequency of venographically
proven DVT still ranges from 16% to 30%.3
The development of LMWHs has added a new dimension to
the clinical management of thrombotic disorders. LMWHs are
prepared by the enzymatic or chemical depolymerization of
standard heparin. The growing use of LMWH in the prophylaxis
and treatment of acute thrombotic disorders emphasizes the
need for characterization of the platelet effects of these
anticoagulants.4ier Inc.
D, Department of Orthopae-
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Open access under CC BY liceFondaparinux (Arixtra; Organon Sanoﬁ-Synthelabo LLC, Oss,
the Netherlands) a pentasaccharide, is a selective inhibitor of
coagulation factor Xa and interrupts the coagulation cascade by
inhibiting thrombin generation without inactivating thrombin.
This drug has been shown to be superior to LMWHs in the
prevention of DVT after hip or knee replacement, and at least as
effective and as safe as LMWHs and unfractionated heparin in
patients with pulmonary embolism and DVT.5,6
Nadroparin calcium (Fraxipoarine; Sanoﬁ, Winthrop, France) is
an LMWH with a mean molecular weight of 4500 Daltons.
Nadroparine calcium is a fractionated heparin derivative with a
wide clinical spectrum of use as an anticoagulant for thrombo-
prophylaxis to reduce the incidence of DVT.7
In our prospective, randomized study we aimed to assess the
efﬁcacy and safety of fondaparinux compared with nadroparin for
prevention of VTE in patients undergoing elective hip and knee
replacement surgery.Patients and Methods
Patients
Patients of both sexes were eligible if they were aged 25 years
or older and were scheduled for primary elective total hip and
knee replacement surgery.nse.
Table I
Distribution of patients by age, sex, and systemic disease.*
Group I Group II P
Age, y 58.7 (13.6) 60.0 (8.4) 40.05
Women 34 (61.8) 33 (62.2) 40.05
Men 21 (38.2) 20 (37.8) 40.05
Diabetes mellitus 5 (9.1) 4 (7.5) 40.05
Hipertension 12 (21.8) 10 (18.9) 40.05
n Except for age, which is presented as mean (SD), values are given as n (%).
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the same procedure or within 2 weeks after inclusion. We also
excluded patients who had at least 1 of the following criteria:
major orthopedic surgery within the previous 1 month; active
bleeding; acute bacterial endocarditis; documented congenital or
acquired bleeding disorder; current ulceration or angiodysplastic
gastrointestinal disease; history of haemorrhagic stroke or myo-
cardial infarction within the previous 6 months; brain, spinal, or
ophthalmologic surgery within the previous 3 months; history of
malignancy, DVT, or pulmonary embolism; planned indwelling
intrathecal or epidural catheter for more than 6 hours after the
end of surgery; hypersensitivity to heparin, LMWHs, porcine
products, or iodinated contrast media; uncontrolled hypertension
(ie, diastolic blood pressure 4120 mm Hg, systolic blood pressure
4200 mm Hg); platelet count o100103/mL; hepatic and renal
insufﬁciency; or anticoagulant treatment or any type of anti-
coagulant or ﬁbrinolytic therapy or dextran within the 2 days
preceding the ﬁrst administration of the study drug.
Study design
This open, prospective, comparative randomized study was
carried out in a university hospital medical center over a period of
1 year. A total of 115 patients were randomized into 2 treatment
groups.
In Group I, patients were assigned to once-daily subcutaneous
injections of 2.5 mg fondaparinux 6 hours before surgery. The ﬁrst
injection of fondaparinux took place a mean of 12 hours after the
operation and subsequent injections of 2.5 mg fondaparinux was
given once daily.
In Group II, the ﬁrst subcutaneous injection of nadroparin
calcium was given 12 hours before surgery, the second 12 hours
after completion of surgery, and subsequent injections once daily
in the morning. The dose of the nadroparin was arranged in
accordance with the manufacturer’s recommendation.
The day of surgery was deﬁned as Day 1 and the efﬁcacy
outcome was assessed on Day 5 and Day 21. During follow-up,
patients were instructed to report any symptoms or signs of
venous thromboembolism or bleeding, and any other clinical
event that arose after treatment had been completed. If VTE arose
during the study, treatment was left to the discretion of the
investigator.
Intra- and postoperative bleeding was assessed, ﬁrst according
to the clinical impression of the surgeon (recorded as normal,
greater than normal, or less than normal), and then by recording
the blood loss collected by suction and swabs, drainage volume,
and the number and amount of blood transfusions.
Throughout the treatment period, intermittent pneumatic
compression, dextran, thrombolytic treatment, and any other
anticoagulant agents were prohibited. The patients were advised
to avoid taking aspirin or nonsteroidal anti-inﬂammatory drugs
whenever possible. Use of graduated compression stockings and
physiotherapy was recommended.
Measurements, including blood counts, clinical biochemical
tests, and coagulation tests were done before the surgical proce-
dure and on the ﬁfth and 21st days after surgery. Blood counts
included hemoglobin and heamatocrit levels and platelet counts;
clinical biochemical tests included alanine aminotransferase,
aspartate aminotransferase, blood urea nitrogen, creatinine, and
direct and indirect bilirubin. Coagulation tests included thrombin
time, partial thromboplastin time, activated partial thromboplas-
tin time, ﬁbrinogen, prothrombin time-International Normalized
Ratio, antithrombin III activity, anti-factor Xa activity, and anti-IIa
activity.
Bruising of the wound area was assessed by the same observer
with use of a subjective visual analog scale described by Warwicket al8 on the ﬁfth and 21st postoperative days. With regard to
bruising, a score of 0 points indicated no discoloration, 1 point
indicated light-yellow discoloration, 2 points indicated dark-
yellow discoloration, 3 points indicated yellow discoloration
greater than the area of 3 palms, 4 points indicated yellow-and-
black discoloration, and 5 points indicated yellow-and-black
discoloration greater than the area of 3 palms.
The study was done in accordance with the ethical principles
in the Declaration of Helsinki. The ethics committee of the
university approved the protocol, and written informed consent
was obtained from all patients before randomization.Statıstical Analysıs
All statistical analysis was performed using SPSS 10.0 for
Windows (IBM Corp, Armonk, New York). A P value of 0.05 or
less was considered statistically signiﬁcant. The outcomes were
compared with use of the t test, the w2 test, the Mann-Whitney U
test with a Bonferroni correction, and repeated measures analysis
of variance test as appropriate.Results
A total of 115 patients were randomized to receive either
fondaparinux or nadroparin into 2 treatment groups over a period
of 1 year.
Thirty-eight of 60 patients in Group I underwent total hip
arthroplasty (THA), remaining 22 underwent total knee artho-
plasty (TKA). Two THA and 3 TKA patients were excluded from the
study due to the postoperative hematoma that was treated with
drainage. Twenty-eight of 55 patients in Group II underwent THA,
the remaining 27 underwent TKA. Two of the TKA patients were
excluded from the study due to postoperative wound hematoma
that was treated with drainage. There was not a signiﬁcant
difference between the groups in terms of hematoma frequency
(P 4 0.05). Serious adverse effects like thrombocytopenia, ane-
mia, and allergy were not seen in either group. The remaining 55
(91.7%) patients in Group I and 53 (96.4%) patients in Group II
completed the study (P 4 0.05).
Baseline characteristics, including age, sex distribution of the
patients, and the number of patients who had systemic disease
like diabetes and hypertension were similar in both groups (see
Table I) (P 4 0.05).
The intraoperative blood loss, whether judged clinically or
according to aspirated volume, and the mean volume of intra-
operative blood transfusion did not show statistically signiﬁcant
differences in either group (P 4 0.05).
When we evaluated the blood counts, including hemoglobin
and hematocrit levels and platelet counts, we found that there
was no statistically signiﬁcant difference between groups.
Table II
The results of clinical biochemical tests of both groups on Day 1, 5, and 21.*
Test Day 1 Day 5 Day 21 F Py Pz Py PJ
BUN, mg/dL
Group I 16.7 (6.6) 17.8 (11.4) 17.1 (8.0) 6.7 0.07 0.26 0.09 0.29
Group II 14.8 (3.9) 14.2 (3.7) 14.9 (4.4) 1.08 0.35
Creatinin, mg/dL
Group I 0.78 (0.2) 0.9 (0.57) 0.95 (0.5) 1.5 0.24 0.30 0.30 0.10
Group II 0.74 (0.1) 0.78 (0.1) 0.7 (0.16) 2.4 0.10
AST, U/I
Group I 24.8 (6.0) 31.5 (12.4) 26.3 (9.4) 2.8 0.08 0.07 0.06 0.15
Group II 23.0 (4.9) 26.2 (7.1) 21.6 (6.1) 1.2 0.3
ALT, U/I
Group I 21.5 (14.3) 18.6 (9.4) 20.8 (8.8) 0.54 0.60 0.7 0.06 0.11
Group II 22.6 (6.2) 23.7 (10.0) 25.2 (6.9) 2.02 0.15
Tbil, mg/dL
Group I 0.76 (0.25) 0.78 (0.17) 0.86 (0.27) 1.4 0.26 0.23 0.97 0.09
Group II 0.72 (0.26) 0.75 (0.3) 0.71 (0.2) 5.7 0.11
Ibil, mg/Dl
Group I 0.19 (0.96) 0.21 (0.11) 0.24 (0.16) 6.0 0.05 0.58 0.62 0.06
Group II 0.20 (0.91) 0.23 (0.14) 0.21 (0.1) 6.2 0.07
AST, aspartate aminotransferase; BUN, blood urea nitrogen; Ibil, indirect bilirubin; Tbil, total bilirubin.
n Values for Days 1, 5, and 21 are given as mean (SD).
y Value for the comparison of a parameter in a group between the days.
z Value for the comparison of a parameter between groups on Day 1.
y Value for the comparison of a parameter between groups on Day 5.
J Value for the comparison of a parameter between groups on Day 21.
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are presented in Table II and the results of coagulation tests are
shown in Table III.
Clinical biochemical tests, including alanine aminotransferase,
aspartate aminotransferase, blood urea nitrogen, creatinine,
direct and indirect bilirubin, and coagulation tests, including
thrombin time, partial thromboplastin time, activated partial
thromboplastin time, ﬁbrinogen, prothrombin time, prothrombinTable III
Results of coagulation tests of both groups on Day 1,5, and 21.*
Test Day 1 Day 5 Day 21
TT, sec
Group I 12.5 (0.7) 12.3 (1.0) 12.6 (0.9
Group II 12.1 (0.4) 12.4 (0.6) 12.5 (0.7
PTZ, sec
Group I 11.9 (0.9) 12.2 (0.7) 12.4 (0.5
Group II 12.0 (0.8) 12.3 (1.2) 12.5 (0.7
aPTT, sec
Group I 28.7 (3.6) 29.5 (3.6) 29.4 (2.9
Group II 27.7 (1.7) 28.3 (2.9) 27.4 (4.7
PT-INR
Group I 0.94 (0.11) 0.95 (0.2) 0.96 (0.0
Group II 0.95 (0.08) 0.97 (0.1) 0.98 (0.1
Fibrinogen, mg/dL
Group I 407.0 (69.4) 606.0 (131.0) 592.0 (12
Group II 398 (94.6) 595.0 (152.0) 594.0 (19
AT-III, %
Group I 110.0 (10.4) 108.5 (12.6) 111.5 (12
Group II 112.7 (13.0) 113.7 (22.4) 109.0 (19
Anti-IIa, %
Group I 83.8 (26.2) 80.6 (17.5) 86.5 (23.
Group II 98.2 (17.7) 103.6 (23.3) 101.8 (18
Anti-Xa, U/mL
Group I 0.03 (0.04) 0.2 (0.12) 0.19 (0.1
Group II 0.01 (0.006) 0.16 (0.12) 0.18 (0.1
Anti-FIIa, antifactor IIa; Anti-Xa, anticoagulation factor Xa; aPTT, activated partial thro
Normalized Ratio; PTZ, partial thromboplastin time; TT, thrombin time.
n Values for Days 1, 5, and 21 are given as mean (SD).
y Value for the comparison of a parameter in a group between the days.
z Value for the comparison of a parameter between groups on Day 1.
y Value for the comparison of a parameter between groups on Day 5.
J Value for the comparison of a parameter between groups on Day 21.time-International Normalized Ratio, and antithrombin III activ-
ity did not show statistically signiﬁcant differences between
Group I and Group II (P 4 0.05). In both study groups, antifactor
Xa activities increased signiﬁcantly on the ﬁfth and 21st day
(P o 0.05). The antifactor Xa activity was higher in the fondapar-
inux group than the nadroparin group. Although the anti-IIa
activity did not show signiﬁcance between days (P 4 0.05), it
showed signiﬁcance between groups on Day 1, Day 5, and Day 21F Py Pz Py PJ
0.06 0.90 0.88
) 2.2 0.13
) 2.5 0.09
0.40 0.45 0.70
) 5.1 0.16
) 6.1 0.06
0.27 0.36 0.11
) 0.6 0.56
) 6.4 0.06
0.56 0.18 0.14
9) 4.0 0.23
) 5.3 0.08
0.60 0.08 0.95
5.0) 36.0 0.07
7.0) 27.7 0.11
0.45 0.26 0.06
.5) 0.02 0.98
.5) 7.5 0.09
0.03 0.02 0.04
2) 4.4 0.10
.6) 4.3 0.13
0.13 0.35 0.99
0) 34.1 0.01
3) 21.7 0.01
mboplastin time; AT III, antithrombin III; PT INR, prothrombin time-International
Table IV
Visual analog scale scores.
Group n Day 5 (0-5) Day 21 (0-5) P*
Group I 55 2.63 2.61 0.58
Group II 53 2.76 1.43 0.01
Py 0.31 0.01
n Value for the comparison of the score in a group between Days 5 and 21.
y Value for the comparison of the score between groups.
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parin group (P o 0.05).
When we evaluated the scores of the subjective visual analog
scale, although there was not a statistically signiﬁcant difference
between groups on the ﬁfth day, we found signiﬁcance on Day 21
(Table IV).
Only 1 proximal DVT occurred in a patient in Group II at the
19th day, which was conﬁrmed by Doppler ultrasonography.
None of the patients in the study developed major bleeding
during the study period.Discussion
VTE is a common, serious complication after major orthopedic
surgery of the lower extremities.1,2 Because of the high risk of VTE
and its considerable morbidity and mortality after major ortho-
pedic surgery of the lower extremities, the routine use of VTE
prophylaxis is recommended for all patients undergoing hip and
knee arthroplasty.2
Studies of the time course of VTE events after THA and TKA
have also demonstrated that when VTE prophylaxis is used, the
period over which patients are at risk is extended beyond 1 week,
and events are likely to occur after a patient is discharged from
the hospital.2,9 A retrospective study in a large group found that
76% of patients who had undergone THA and 47% who had
undergone TKA experienced a VTE event after being discharged
from the hospital.2 Median time of diagnosis of thromboembo-
lism was 17 days with THA and 7 days with TKA. In our study, we
followed patients for 3 weeks, which included the period over
which patients are at high risk.
A meta-analysis of fondaparinux Phase III data in 5385
patients showed that, in patients who have had major orthopedic
surgery, fondaparinux reduced the incidence of VTE to 6.8% and
this result was better than the results of enoxaparin (13.7%).10
Nadroparin thromboprophylaxis is known to reduce the inci-
dence of DVT by 87%. This major decrease in DVT incidence was
not associated with an increased risk of bleeding.11
In the Evaluation of AriXtra for the Prevention of vEnous
thRomboembolism in daily pracTice study12 it was reported that
the overall rate of major bleeding with fondaparinux prophylaxis
was 0.8%, of which 71.4% of cases occurred within 15 days after
surgery. Fatal bleeding and bleeding in a critical organ was
observed in 0.1% of patients. Bleeding at the surgical site leading
to reoperation occurred in 0.5% of patients and bleeding at a
nonsurgical site necessitating the transfusion of 42 units of blood
occurred in 0.1% of patients. In our small study group, bleeding at
the surgical site leading to drainage due to postoperative hema-
toma occured in 8.3% of patients in the fondaparinux group and
3.6% in the nadroparin group. Although the percentage was high
in the fondaparinux group there was not a statistically signiﬁcant
difference between the 2 groups. None of the patients in the
2 groups had bleeding that was fatal or involved a critical organ.
In a Phase III, long-term prophylactic study in hip fracture
surgery, it was reported that there were no differences in the
overall incidence of adverse events and in platelet count betweenthe fondaparinux and placebo groups. However, until the safety of
fondaparinux concerning immune thrombocytopenia is ﬁrmly
established by clinical experience, periodic blood platelet count
monitoring is recommended during the course of fondaparinux
therapy.13 Similarly, an increase in serum transaminases was rare
in both groups.14
In our study, there were no differences between fondaparinux
and nadroparin groups in the blood counts, including hemoglobin
and platelet counts. When we evaluated the serum transami-
nases, although there was a slight increase in the mean value of
AST on the ﬁfth and 21st day in both groups, the difference
showed no signiﬁcance.
It is known that LMWH does not usually elevate activated
partial thromboplastin time; it is valued for its antithrombotic
rather than its anticoagulant effect.15 None of the coagulation
tests showed signiﬁcant changes in either group of our study. In
general, antifactor Xa assays are more sensitive to the effects of
LMWHs and are therefore more useful in this respect than anti-IIa
assays.16,17 Differences were also observed in the antifactor Xa
activities of the LMWHs. All the LMWHs studied had weaker
antifactor Xa potency than standard heparin. We found that
antifactor Xa activities were increased signiﬁcantly on the ﬁfth
and 21st day in our both study groups.
Regarding the subjective visual analog scale, there was sig-
niﬁcantly less bruising and oozing on the 21st day in the
nadroparin group than in the fondapainux group. The clinical
importance of these differences is unclear because it is not known
how they are related to the cost of the dressings, the duration of
hospitalization, the formation of hematomas, or the rate of
infection. Furthermore, the scales for the measurement of bruis-
ing and oozing were subjective and the examination depends on
the observer. Unless these side effects were not to be associated
with the disastrous complication of infection, it would not be
viewed as a disadvantage.
In our prospective study, symptomatic VTE events were rare,
during both the treatment and follow-up periods. Our results
conﬁrm the safety and efﬁcacy of both fondaparinux and nadro-
parin for prophylaxis after major orthopedic surgery of the lower
extremities and showed that neither drug is associated with a risk
of major bleeding complications.Acknowledgments
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